Expert Commentary

The FDA’s review of the data on open power morcellation was “inadequate, irresponsible” and a “disservice to women”

Author and Disclosure Information

Dr. William Parker discusses the FDA's estimate of the incidence of occult uterine malignancy at the time of benign hysterectomy and explains why he considers that estimate inaccurate and "a disservice to women.

He also describes the advantages of laparoscopic morcellation, compared with vaginal morcellation and morcellation through a mini-laparotomy, and summarizes what we know about how survival is affected if a uterine malignancy is inadvertently morcellated during surgery, and more.


 

Recommended Reading

The Extracorporeal C-Incision Tissue Extraction (ExCITE) technique
MDedge ObGyn
Flight plan for robotic surgery credentialing: New AAGL guidelines
MDedge ObGyn
The economics of gynecologic surgery: 13 coding tips to ensure fair payment
MDedge ObGyn
AAGL 2014: Conference social highlights
MDedge ObGyn
Racial, geographic, insurance disparities in endometrial cancer outcomes
MDedge ObGyn
VIDEO: An easy way to improve breast biopsy practices
MDedge ObGyn
Salpingectomy associated with reduced ovarian cancer risk
MDedge ObGyn
Dr. Robert L. Barbieri’s Editor’s Picks November 2014
MDedge ObGyn
Treatment of stress urinary incontinence
MDedge ObGyn
Midurethral slings
MDedge ObGyn

Related Articles